Syqe Medical Ltd.

syqe.com ; www.syqe.co.il

High-Tech Company

TECH VERTICALS

Healthtech, Life Sciences, Medical Cannabis, Medical Devices, MedTech

General Data

Sector	Medical Devices
Company Stage:	Revenue Growth
Established	2011
Number of Employees	104
Reg. Number:	abCDe

DESCRIPTION

Syqe Medical is an innovative MedTech company that developed a breakthrough technology for the administration of medical cannabis by inhalation. Syqe developed the SyqeAir Inhaler – a unique technology that allows physicians and patients to manage cannabis treatment in compliance with the principles of the standard of care of metered dosing, lowest effective dose, and safety of use.

TECHNOLOGY

SyqeAir Inhaler - Device delivering metered THC doses.
VaporChips™ & Cartridges - Pre-measured cannabis doses in secure cartridges.
Electronic Selective‑Dose™, ActiveFlow™, PulseBreath™- Core patented technologies ensuring accurate, uniform, and safe dose delivery.
Data Logging & App Integration.

Products and Phases

Product	Phase
SyqeAir Inhaler	Approved CE Approved MDL, ARTG, AMAR
With each inhalation, a consistent and metered amount of THC is released from a raw medical cannabis inflorescence with a full, uniform, and consistent spectrum of the active ingredients. The cannabis is sealed in a designated cartridge, which is loaded securely into the Inhaler, ready for use. The cartridge contains 60 VaporChips (each the size of a sim card), and each VaporChip contains a uniform amount of raw cannabis inflorescence grown in compliance with GMP’s strict production requirements.
Syqe Inhaler Exo	Approved The Israeli Ministry of Health
A hospital version metered-dose cannabis inhaler for professional healthcare use, featuring a caregiver interface. Aimed at providing nurses and caregivers with a certified medical device for use in pain clinics, cancer centers, intensive care units and other medical institutions.

	TARGET MARKETS
	Physicians, Patients.

	BUSINESS MODEL
	B2C

Patents

Expand / Collapse All

Publication ID/Number

Patent Title

Status

Initial Filing Date

US9775379B2

Method and system for drug delivery

Granted

Dec. 22, 2011

Grant Date	Oct. 03, 2017
Jurisdictional Coverage	PL CA EP WO IL ES US
Technology Classification	A61K9/0004
Description	The invention involves a device and method for extracting active substances from plant matter using heat. The device includes a heating element for applying heat and a mechanism for moving the plant matter. It also includes methods for monitoring inhalation of restricted substances and for manufacturing plant matter tape with active substances.
Expiration Date	Sep. 26, 2034
Publication Date	Oct. 24, 2013
Rejection Date
Web Link	https://patents.google.com/patent/US9775379B2
Remarks

SERVICE PROVIDERS

Company Name	Type
abC Defghij	Law Firm

REMARKS

Date	Remark
18/07/2023	Philip Morris announced the acquisition of Syqe Medical for $650m, with an Initial investment of $120m to support the process of obtaining FDA approval. The transaction's completion is subject to receiving this approval.

CONTACT INFO

Expand / Collapse All

Main Address: Tel Aviv, Israel

Address	14 Hatchiya St., Entrance A, Studio 211
City	Tel Aviv
Country	Israel
Zip	6816914

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title	Previous Position
Mr. Perry Davidson	CEO & Co-Founder
Ms. Hagit Kamin	CEO, SyqeAir
Mr. Ido Zur	CFO & COO	Ripples (CFO)
Mr. Benjamin Schwartz	CEO, SyqePharma Business Unit & Co-Founder
Mr. Roi Ram	VP, R&D	Donisi (VP, R&D)
Mr. Roee Lifshitz	Chief Pharmaceutical Engineering
Mr. Jacob Vogel	Director of Global Sales & Business Development
Ms. Lior Levin	Chief People & Organizational Excellence

	BOARD

Board

Member	Title	Affiliation
abC Defghij	Board Member	Managing Partner & Founder, Shavit Capital
abC Defghij	Board Member	N\A
abC Defghij	Board Member	CEO & Founder, Syqe Medical

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

Second Round

Dec. 31, 2018

Initial Revenues

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe	Led the round
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Corporate VC	abCDe
abC Defghij	Institutional Investor	abCDe
abC Defghij	Investment Company	abCDe
abC Defghij	Investment Company	abCDe
abC Defghij	Angel Syndicate	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Retail	abCDe
abC Defghij	Private Investor	abCDe

First Round - Extended

Jan. 19, 2016

R&D

abCDe

First Round

Jun. 11, 2015

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Angel Syndicate	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe

Seed

Jan. 01, 2013

Seed

abCDe

	R&D Grants

Expand / Collapse All

Round

Date

Stage

Amount

Remarks

R&D Grant

Jun. 01, 2018

Initial Revenues

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij*	Government Agency	abCDe

Last Updated:	abCDe
IVC Number:	abCDe